Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices 10313 

treaties, conventions, or protocols in 

effect on May 1, 1971, at this time. DEA 

has investigated Hospira Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: February 26, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–4770 Filed 3–4–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances 

Notice of Registration 

By Notice dated October 21, 2009, and 

published in the Federal Register on 

October 28, 2009 (74 FR 55584), 

Cerilliant Corporation, 811 Paloma 

Drive, Suite A, Round Rock, Texas 

78665–2402, made application via the 

Internet to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of 5-Methoxy-N,Ndiisopropyltryptamine (7439), a basic 

class of controlled substance listed in 

schedule I. 

The company plans to import small 

quantities of the listed controlled 

substance for the manufacture of 

analytical reference standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and § 952(a), 

and determined that the registration of 

Cerilliant Corporation to import the 

basic class of controlled substance is 

consistent with the public interest, and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Cerilliant Corporation to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: February 26, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–4771 Filed 3–4–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on November 6, 2009, 

Mallinckrodt Inc., 3600 North Second 

Street, St. Louis, Missouri 63147, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Codeine-N-oxide (9053) ............... I 

Dihydromorphine (9145) ............... I 

Difenoxin (9168) ........................... I 

Morphine-N-oxide (9307) ............. I 

Normorphine (9313) ..................... I 

Norlevorphanol (9634) .................. I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Codeine (9050) ............................. II 

Diprenorphine (9058) ................... II 

Etorphine HCl (9059) ................... II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone Intermediate (9254) ... II 

Metopon (9260) ............................ II 

Dextropropoxyphene, bulk (9273) II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Opium extracts (9610) .................. II 

Opium fluid extract (9620) ............ II 

Opium tincture (9630) .................. II 

Opium, powdered (9639) ............. II 

Opium, granulated (9640) ............ II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Drug Schedule 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The firm plans to manufacture the 

listed controlled substances for internal 

use and for sale to other companies. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than May 4, 2010. 

Dated: February 26, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–4717 Filed 3–4–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 16, 2009, and 

published in the Federal Register on 

October 28, 2009, (74 FR 55586), Lonza 

Riverside, 900 River Road, 

Conshohocken, Pennsylvania 19428, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Gamma hydroxybutyric acid 

(2010).

I 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

The company plans to manufacture 

bulk products for finished dosage units 

and distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Lonza Riverside to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Lonza Riverside to ensure 


erowe on DSK5CLS3C1PROD with NOTICES